Randell, Rachel L. http://orcid.org/0000-0002-8009-8209
Stern, Sara M.
Van Mater, Heather
Schanberg, Laura E.
Lieberman, Scott M.
Basiaga, Matthew L.
,
,
Article History
Received: 19 May 2022
Accepted: 29 August 2022
First Online: 5 September 2022
Declarations
:
: The project was declared exempt by the Duke Health Institutional Review Board (Pro00103458).
: RLR’s spouse has financial relationships with Merck and Biogen. LES has received research funds from Bristol Myers Squibb and CARRA. LES serves on the data and safety monitoring board for Sanofi (sarilumab) and UCB (certolizumab). LES is a former President and currently sits on the Registry and Research Oversight Committee for CARRA.